Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-17-041474
Filing Date
2017-06-22
Accepted
2017-06-22 19:26:25
Documents
2
Period of Report
2017-06-22

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 5839
2 POA DOCUMENT poa.txt EX-24.4_732835 4396
  Complete submission text file 0001209191-17-041474.txt   11588
Mailing Address C/O OREXIGEN THERAPEUTICS, INC. 3344 N TORREY PINES CT, #200 LA JOLLA CA 92037
Business Address
NARACHI MICHAEL (Reporting) CIK: 0001380022 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36276 | Film No.: 17926110

Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Issuer) CIK: 0001515673 (see all company filings)

EIN.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations